Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Immix Biopharma, Inc. Common Stock (IMMX)

Pharmaceutical Preparations

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.

11400 WEST OLYMPIC BLVD., SUITE 200
LOS ANGELES, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/16/2021

Market Cap

51,057,893

Shares Outstanding

19,870,000

Weighted SO

19,867,224

Total Employees

N/A

Upcoming Earnings

08/09/2024

Beta

0.1660

Last Div

0.0000

Range

1.58-7.75

Chg

-0.0300

Avg Vol

158248

Mkt Cap

51057893

Exch

NASDAQ

Country

US

Phone

310 651 8041

DCF Diff

0.8403

DCF

1.0097

Div Yield

0.0000

P/S

10672.6365

EV Multiple

-1.4085

P/FV

2.2410

Div Yield %

0.0000

P/E

-2.8146

PEG

0.0646

Payout

0.0000

Current Ratio

7.0045

Quick Ratio

7.0045

Cash Ratio

6.1444

DSO

151087.1112

DIO

0.0000

Op Cycle

151087.1112

DPO

16283.1620

CCC

134803.9493

Gross Margin

-9.9954

Op Margin

-4231.1467

Pretax Margin

-4013.8353

Net Margin

-3976.1904

Eff Tax Rate

-0.0018

ROA

-0.6597

ROE

-0.8648

ROCE

-0.8118

NI/EBT

0.9906

EBT/EBIT

0.9486

EBIT/Rev

-4231.1467

Debt Ratio

0.0378

D/E

0.0457

LT Debt/Cap

0.0418

Total Debt/Cap

0.0437

Int Coverage

-437.5661

CF/Debt

-12.0113

Equity Multi

1.2070

Rec Turnover

0.0024

Pay Turnover

0.0224

Inv Turnover

0.0000

FA Turnover

0.0032

Asset Turnover

0.0002

OCF/Share

-0.4553

FCF/Share

-0.4676

Cash/Share

0.8329

OCF/Sales

-2739.6087

FCF/OCF

1.0270

CF Coverage

-12.0113

ST Coverage

-271.0207

CapEx Coverage

-37.0232

Div&CapEx Cov

-37.0232

P/BV

2.2410

P/B

2.2410

P/S

10672.6365

P/E

-2.8146

P/FCF

-3.7932

P/OCF

-4.0851

P/CF

-4.0851

PEG

0.0646

P/S

10672.6365

EV Multiple

-1.4085

P/FV

2.2410

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 26, 01:31 California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) GlobeNewswire Inc. Jan 04, 09:34 Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board GlobeNewswire Inc. Dec 18, 09:39 Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board GlobeNewswire Inc. Dec 11, 09:36 Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 Seeking Alpha Dec 03, 02:02 Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status Seeking Alpha Dec 03, 02:02 Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status Seeking Alpha Dec 03, 02:02 Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status GlobeNewswire Inc. Nov 30, 09:46 Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit GlobeNewswire Inc. Nov 22, 09:19 Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis GlobeNewswire Inc. Nov 22, 03:20 La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains GlobeNewswire Inc. Nov 22, 03:20 Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht GlobeNewswire Inc. Nov 22, 03:20 La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains GlobeNewswire Inc. Nov 22, 03:20 Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht GlobeNewswire Inc. Nov 21, 09:46 Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing GlobeNewswire Inc. Nov 21, 09:46 Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing GlobeNewswire Inc. Nov 06, 09:12 Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients GlobeNewswire Inc. Nov 06, 08:40 Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Revenue Product Segmentation